For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.
Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research
Author: Simge Eva DoganPublished: 26 July 2018
Prep: Cook: Serves:
Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.
The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.
The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.
Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”
For more information on this article click here.
Share this story
Parkinson’s AI trial launched by Chinese tech giant
The study will take place in LondonREAD MORE
How to combat sleeping problems caused by Parkinson’s
Register for this free, hour-long webinarREAD MORE
Parkinson’s podcast: ‘New Neurons for Old’ – interview with Dr Roger Barker
The controversial history of foetal tissue and stem cell therapiesREAD MORE